Hemostatic profile and safety of pooled cryoprecipitate up to 120 hours after thawing

Transfusion

Volumn 58, Issue 5, 2018, Pages 1126-1131

  Lokhandwala, Parvez M ^a   O'Neal, Adrian ^a   Patel, Eshan U ^a   Brunker, Patricia A R ^a,b   Gehrie, Eric A ^a   Zheng, Gang ^a   Kickler, Thomas S ^a   Ness, Paul M ^a   Tobian, Aaron A R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; HEMOSTATIC AGENT; VON WILLEBRAND FACTOR;

BLOOD SAFETY; BLOOD STORAGE; CRYOPRESERVATION; HUMAN; INFERTILITY; TEMPERATURE; TIME FACTOR;

BLOOD PRESERVATION; BLOOD SAFETY; CRYOPRESERVATION; FACTOR VIII; FIBRINOGEN; HEMOSTATICS; HUMANS; INFERTILITY; TEMPERATURE; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 85042406460     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14550     Document Type: Article

References (27)

1. Dumont LJ, Papari M, Aronson CA, Dumont DF. Whole-blood collection and component processing. In: Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, editors. Technical manual. Bethesda (MD): AABB; 2014.
2. Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA 1979;241:1690-1.
3. AABB, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of information for the use of human blood and blood components [Internet]; 2013 [cited 2017 Nov 20]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM364587.pdf.
4. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014;54:1389-405.
5. Hagemo JS, Stanworth S, Juffermans NP, et al. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. Crit Care 2014;18:R52
6. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007;13:680-5.
7. Kauvar DS, Wade CE. The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care 2005;9: S1-9.
8. Janson PA, Jubelirer SJ, Weinstein MJ, et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980;303:1318-22.
9. AABB. Standards for blood banks and transfusion services. 30th ed. Bethesda (MD): AABB; 2016.
10. Sheffield WP, Bhakta V, Jenkins C. Stability of coagulation protein activities in single units or pools of cryoprecipitate during storage at 20-24 degrees C for up to 24 h. Vox Sang 2016;110:12-9.
11. Green L, Backholer L, Wiltshire M, et al. The hemostatic properties of thawed pooled cryoprecipitate up to 72 hours. Transfusion 2016;56:1356-61.
12. Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat Med 2009;28:221-39.
13. Twisk JWR. Applied longitudinal data analysis for epidemiology: a practical guide. 2nd ed. Cambridge: Cambridge University Press; 2013.
14. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012;10:1342-51.
15. Innerhofer P, Westermann I, Tauber H, et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 2013;44:209-16.
16. Morrison JJ, Ross JD, Dubose JJ, et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg 2013;148:218-25.
17. Guidelines for the blood transfusion services in the United Kingdom. 8th ed. London: The Stationery Office, 2013.
18. Canadian Blood Services. Circular of information for the use of human blood components. Ottawa, Canada: Canadian Blood Services; 1999.
19. Winearls J, Wullschleger M, Wake E, et al. Fibrinogen early in severe trauma study (FEISTY): study protocol for a randomised controlled trial. Trials 2017;18:241
20. Spivey MA, Jeter EK, Lazarchick J, et al. Postfiltration factor VIII and fibrinogen levels in cryoprecipitate stored at room temperature and at 1 to 6 degrees C. Transfusion 1992;32:340-3.
21. Keller-Stanislawski B, Lohmann A, Gunay S, et al. The German Haemovigilance System—reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009;19:340-9.
22. Ramirez-Arcos S, Jenkins C, Sheffield WP. Bacteria can proliferate in thawed cryoprecipitate stored at room temperature for longer than 4 h. Vox Sang 2017;112:477-9.
23. Jacobs MR, Smith D, Heaton WA, et al. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011;51:2573-82.
24. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion: draft guidance for industry [Internet]; March 2016 [cited 2017 Feb 16]. Available from: https://www.fda.gov/downloads/Guidances/Blood/UCM425952.pdf.
25. Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma. Transfus Apher Sci 2012;46:153-8.
26. Cid J, Caballo C, Pino M, et al. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion 2013;53:600-5.
27. Bloch EM, Marshall CE, et al. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Paper presented at the AABB Annual Meeting, San Diego, October 7-10, 2017.